Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround

Emergent Biosolutions ( (EBS) ) has issued an announcement.

On April 30, 2026, Emergent BioSolutions reported first-quarter 2026 results showing total revenue of $156.1 million, net income of $6.8 million with a 4% margin, and adjusted EBITDA of $35.6 million, all down sharply versus the prior year period despite beating its own guidance. Management highlighted debt refinancing to lower interest costs, a share repurchase authorization of up to $50 million through March 2027, and a continued turnaround strategy focused on building profitable verticals.

Revenue declined 30% year on year as weaker anthrax and smallpox medical countermeasure sales to government customers and softer over-the-counter NARCAN volumes more than offset gains in other products, though the company maintained NARCAN market share and expanded its offering with new carrying case and multipack options. Recent moves included new manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics, substantial contract wins with the U.S. and Canadian governments for smallpox and anthrax countermeasures, regulatory progress for ACAM2000’s mpox indication, and brand-building initiatives for NARCAN in North America, underscoring an effort to stabilize revenue while reinforcing its role in biodefense and opioid overdose preparedness.

The most recent analyst rating on (EBS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Spark’s Take on EBS Stock

According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.

The score is driven primarily by improving financial performance and strong 2025 cash generation, but tempered by revenue contraction, historical volatility, and leverage. Technicals remain a headwind with negative MACD and the stock below key longer-term moving averages. Valuation is reasonable on P/E, while the earnings outlook is mixed due to weaker 2026 profitability guidance and an expected GAAP loss.

To see Spark’s full report on EBS stock, click here.

More about Emergent Biosolutions

Emergent BioSolutions Inc. is a specialty biopharmaceutical company focused on medical countermeasures and public health threat preparedness, with a portfolio that includes naloxone products such as NARCAN Nasal Spray and KLOXXADO, anthrax vaccines like BioThrax and CYFENDUS, and smallpox and mpox vaccines including ACAM2000 and TEMBEXA, serving government and commercial customers worldwide. The company also provides contract manufacturing services and leverages facilities such as its Canton site through strategic partnerships for biologics development and vaccine production.

Average Trading Volume: 843,659

Technical Sentiment Signal: Sell

Current Market Cap: $412.6M

For an in-depth examination of EBS stock, go to TipRanks’ Overview page.